Anavex Life Sciences Corp (AVXL)

[XenaLives]

makemydaze Wednesday, 04/13/16 08:29:42 AM
Re: georgejjl post# 59096
Post #59099 of 83471

Jackie French will be there but she is affiliated with so many companies that it may not mean anything for Anavex specifically.

"Jacqueline French
(Education Program, Science Program) (C169, PL6, P2, S22, I5)

The Epilepsy Study Consortium pays Dr French’s university employer for her consultant time related to Acorda, Alexza, Anavex, BioPharm Solutions, Concert Pharmaceuticals, Eisai, Georgia Regents University, GW Pharma, Marinus, Monteris, Nestle-Health Science, Neurelis, Novartis, Pfizer, Pfizer-Neusentis, Pronutria, Roivant, Sage, SciFluor, SK Life Sciences, Sunovion, Takeda, UCB Inc., Upsher Smith, Xenon Pharmaceuticals, Zogenix.. Personal compensation for Associate Editor Epilepsia. She has received grants and research from Acorda, Alexza, LCGH, Eisai Medical Research, Lundbeck, Pfizer, SK life sciences, UCB, Upsher-Smith, Vertex, grants from NINDS, Epilepsy Therapy Project, Epilepsy Research Foundation, Epilepsy Study Consortium."

http://tools.aan.com/annualmeeting/search/index.cfm?fuseaction=disclosures.home&meetingyear=2016&lastname=french&search=Search

There is no "Missling" listed but feel free to search for any of your favorite Anavex stars.

XenaLives Member Level Friday, 06/17/16 02:23:14 AM
Re: None
Post #65372 of 83471

Example of Takeda licensing deal - this is GI but they also focus on CNS. $15 million up front. Alzheimer's is a much bigger market.

http://finance.yahoo.com/news/takeda-licenses-global-rights-theravance-122900801.html

XenaLives Member Level Friday, 09/16/16 07:42:21 AM
Re: georgejjl post# 75321
Post #75322 of 83471

About Agreement Reached to Co-market R113675 (Galantamine Hydrobromide),
a Treatment for Alzheimer's Disease

OSAKA, Japan, April 1, 2010 --- Takeda Pharmaceutical Company Limited (“Takeda”) today announced that it has signed an agreement dated March 31, 2010 with JANSSEN PHARMACEUTICAL K.K. (Head Office: Tokyo, President: Toon Overstijns, hereinafter called “Janssen Pharma”) and Janssen Pharmaceutica N.V. (Head Office: Belgium, Managing Director: Tom Heyman) regarding co-marketing in Japan of galantamine (R113675), which is a drug for Alzheimer's Disease and chemically known as galantamine hydrobromide (hereinafter called “galantamine”).

Following the development of galantamine by Janssen Pharmaceutica, for the treatment of Alzheimer’s Disease in Japan, Janssen Pharma submitted an application for approval to the Ministry of Health, Labor and Welfare in February 2010. Once approved, Takeda and Janssen Pharma will co-market galantamine under the same brand name.

Under the agreement, Takeda receives rights to co-market galantamine in Japan, and will make an upfront contractual payment, as well as launch & annual sales milestone payments to Janssen Pharma and Janssen Pharmaceutica. In addition, Takeda will pay a fixed rate based on sales. Other contractual details are not disclosed.

For Takeda, this agreement will expand and improve its domestic pipeline in CNS (central nervous system) which is one of Takeda’s core therapeutic disease areas. After receiving approval, we look forward to offering a new treatment option for patients suffering from Alzheimer’s Disease, their families and healthcare professionals. At Takeda, we are committed to making continued effort to research, develop and market new medicines that address unmet medical needs.
About Galantamine

Galantamine has a dual mechanism which affect acetylcholinesterase inhibition and nicotinic acetylcholine receptor enhancement that increases concentration of acetylcholine, a key neurotransmitter in the brain. First approved in 2000 in Europe, it has been launched in more than 70 countries around the world. In major treatment guidelines, galantamine is positioned as one of the standard therapies for “mild to moderate Alzheimer’s Disease”.

http://contractservices.pharmaceutical-business-review.com/news/takeda_pharmaceutical_signs_comarketing_agreement_for_galantamine_in_japan_100405

ipulator_man Monday, 07/04/16 02:38:59 PM
Re: basparks79 post# 66858
Post # of 83471

Check out this guy's work:

"Dr. Castellani, Ms. Gupta, Ms. Siedlak, Ms. Harris, Dr. Coller, and Dr. Tabaton report no conflict of interests. Dr. Perry is a consultant for Takeda Pharmaceuticals and Neurotez and owns stock options in Neurotez and Voyager. Dr. Zhu was a consultant for and received grant support from Medivation. Dr. Smith was a consultant for Anavex Life Sciences Corporation, Eisai, Medivation, Neurotez, and Takeda Pharmaceuticals; owned stock options in Aria Neurosciences, Neurotez, Panancea, and Voyager, and had received lecture fees from GSK, Medivation, and Pfizer."

He had just joined the team when he died in 2010.
http://www.case.edu/med/pathology/faculty/smith.html

The MOA of Anavex' compounds tie in with his theories precisely. He would have been a powerful ally.
§